News Releases

October 15, 2021
Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
- Real-world evidence dataset demonstrates relationship between higher urinary oxalate levels and increased incidence of chronic kidney disease - - Additional clinical data presented on SYNB8802 in a healthy volunteer model of diet-induced hyperoxaluria - - Phase 1b study of SYNB8802 in enteric...
October 12, 2021
Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform
CAMBRIDGE, Mass. , Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic products designed using the...
September 27, 2021
Synlogic Appoints Molly Harper as Chief Business Officer
CAMBRIDGE, Mass. , Sept. 27, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms....
September 22, 2021
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering...
September 22, 2021
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....
September 20, 2021
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
-- SYNB1618 demonstrated proof of concept with meaningful reduction of plasma phenylalanine (Phe) levels in an interim analysis of the Phase 2 SynPheny-1 Study -- -- SYNB1934, an optimized strain of SYNB1618, demonstrated two-fold increase in biomarkers of Phe metabolism compared to SYNB1618 -- --...
September 10, 2021
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
CAMBRIDGE, Mass. , Sept. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of...
September 10, 2021
Synlogic Presents at Global PKU Patient Meeting
- Results of patient and caregiver survey highlight unmet need in PKU, burden of disease, and benefits from addition of natural protein to diet - CAMBRIDGE, Mass. , Sept. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of...
August 12, 2021
Synlogic Reports Second Quarter Financial Results and Provides Business Update
- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - Immunomodulation portfolio expanded via strategic research collaboration in IBD - - Synlogic ends 2Q 2021 with $115.5 million in cash, cash equivalents...
August 5, 2021
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
CAMBRIDGE, Mass. , Aug. 5, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2021 financial results before the market opens on Thursday,...
July 22, 2021
Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)
- Data show dose-responsive, non-saturated increases in gastrointestinal consumption of Phe in humans by SYNB1618 - - SYNB1618 Phase 2 study in patients with PKU ongoing with proof-of-concept readout anticipated in 2H 2021 - - Phase 1 study of SYNB1934, an evolved strain of SYNB1618 in the PKU...
July 15, 2021
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
- SYNB1934, an evolved strain of SYNB1618, has the potential to provide increased benefit to patients living with PKU - - SYNB1934 Phase 1 Study to evaluate safety, tolerability, and head-to-head comparison of biomarkers of Phe-consumption between SYNB1934 and SYNB1618 - - SYNB1618 Phase 2 Study in...
Displaying 1 - 12 of 156